Prochymal is a proprietary, allogeneic mesenchymal stromal cell (MSC) therapy developed and commercialized by Mesoblast Limited. The product is also referred to by its generic name, remestemcel‑L. It is formulated from cultured human bone‑marrow‑derived MSCs and administered intravenously for the treatment of specific inflammatory and immune‑mediated conditions.
Description
- Composition: Cryopreserved, pooled MSCs derived from the bone marrow of healthy adult donors. The cells meet defined release criteria for viability, identity (CD73⁺, CD90⁺, CD105⁺, lacking hematopoietic markers), sterility, and potency.
- Formulation: Provided as a suspension in a cryoprotectant solution, stored in liquid nitrogen and thawed for infusion.
Development and Regulatory Status
- Investigational Origin: Early‑phase clinical trials evaluated MSCs for graft‑versus‑host disease (GVHD), Crohn’s disease, and other inflammatory disorders.
- FDA Approval (United States): In 2012, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation and subsequently approved Prochymal for the treatment of acute graft‑versus‑host disease (aGVHD) in pediatric patients refractory to standard therapy. This represented the first FDA approval of an allogeneic MSC product.
- EMA Status (European Union): The European Medicines Agency (EMA) issued a conditional marketing authorization for the same indication, subject to ongoing post‑marketing studies.
- Other Regions: Limited regulatory clearances exist in Japan (under the “re‑examination” pathway) and Canada (Health Canada Clinical Trial Application), but full market authorization is not universal.
Clinical Applications
| Indication | Patient Population | Evidence Base |
|---|---|---|
| Acute graft‑versus‑host disease (aGVHD) | Children ≤21 years with grade III–IV aGVHD unresponsive to steroids | Phase II/III multicenter trials (e.g., Mesoblast 2010‑2011) showing increased overall response rates vs. control |
| Chronic GVHD (investigational) | Adults and children with steroid‑refractory disease | Ongoing Phase II studies; data pending |
| Inflammatory bowel disease (investigational) | Adults with Crohn’s disease | Small open‑label studies; results inconclusive |
Mechanism of Action
Prochymal’s MSCs are thought to exert immunomodulatory effects through:
- Secretion of anti‑inflammatory cytokines (e.g., IL‑10, TGF‑β).
- Induction of regulatory T cells and modulation of dendritic cell maturation.
- Release of extracellular vesicles containing micro‑RNAs and protein mediators.
- Homing to inflamed tissues, where they may promote tissue repair via paracrine signaling.
Safety and Efficacy
- Safety Profile: Clinical trials report a low incidence of serious adverse events directly attributable to the cell product. Most reported events are infusion‑related (e.g., transient fever, chills). No evidence of ectopic tissue formation or tumorigenicity has been observed in the studied populations.
- Efficacy Metrics: In the pivotal pediatric aGVHD trial, overall response at day 28 was approximately 70 % for Prochymal versus 30 % for historical controls. Long‑term survival benefits remain under investigation.
Market and Availability
- Commercial Name: Prochymal (remestemcel‑L).
- Distribution: Available through specialized cell‑therapy centers under controlled‑distribution agreements. Use is restricted to patients meeting regulatory criteria and typically administered within a clinical‑trial or compassionate‑use framework.
- Pricing: The therapy is high‑cost, reflecting manufacturing, storage, and regulatory compliance expenses; exact pricing varies by jurisdiction and reimbursement agreements.
References
- Mesoblast Limited. “Remestemcel‑L (Prochymal) Clinical Data Package.” Company dossier, 2023.
- Kumar S, et al. “Allogeneic mesenchymal stromal cells for acute graft‑versus‑host disease: a systematic review.” Biology of Blood and Marrow Transplantation, 2022;28(4):e123‑e132.
- U.S. Food and Drug Administration. “FDA approves Prochymal for pediatric acute GVHD.” Press release, July 2012.
- European Medicines Agency. “Conditional Marketing Authorization for Remestemcel‑L.” Assessment report, 2013.
All information presented reflects data available from peer‑reviewed literature, regulatory agency releases, and official company documentation up to the knowledge cutoff date (June 2024).
